Characterization of a Sphingosine 1-Phosphate Receptor Antagonist Prodrug

Perry C. Kennedy, Ran Zhu, Tao Huang, Jose L. Tomsig, Thomas P. Mathews, Marion David, Olivier Peyruchaud, Timothy L. Macdonald, and Kevin R. Lynch

Departments of Pharmacology (P.C.K., J.L.T., K.R.L.) and Chemistry (R.Z., T.H., T.P.M., T.L.M.), University of Virginia, Charlottesville, Virginia; and Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1033, Université de Lyon, Lyon, France (M.D., O.P.)

Received March 13, 2011; accepted May 31, 2011

ABSTRACT

Sphingosine 1-phosphate (S1P) is a phospholipid that binds to a set of G protein-coupled receptors (S1P1–S1P5) to initiate an array of signaling cascades that affect cell survival, differentiation, proliferation, and migration. On a larger physiological scale, the effects of S1P on immune cell trafficking, vascular barrier integrity, angiogenesis, and heart rate have also been observed. An impetus for the characterization of S1P-initiated signaling effects came with the discovery that FTY720 [fingolimod; 2-amino-2-[4-octylphenyl]ethyl]-1,3-propanediol] modulates the immune system by acting as an agonist at S1P1. In the course of structure-activity relationship studies to better understand the functional chemical space around FTY720, we discovered conformationally constrained FTY720 analogs that behave as S1P receptor type-selective antagonists. Here, we present a pharmacological profile of a lead S1P1/3 antagonist prodrug, 1-(hydroxymethyl)-3-(3-octylphenyl)cyclobutane (VPC03090). VPC03090 is phosphorylated by sphingosine kinase 2 to form the competitive antagonist species 3-(3-octylphenyl)-1-(phosphonooxymethyl)cyclobutane (VPC03090-P) as observed in guanosine 5'-O-[3-[35S]thiotriphosphate binding assays, with effects on downstream S1P receptor signaling confirmed by Western blot and calcium mobilization assays. Oral dosing of VPC03090 results in an approximate 1:1 phosphorylated/alcohol species ratio with a half-life of 30 h in mice. Because aberrant S1P signaling has been implicated in carcinogenesis, we applied VPC03090 in an immunocompetent mouse mammary cancer model to assess its antineoplastic potential. Treatment with VPC03090 significantly inhibited the growth of 4T1 primary tumors in mice. This result calls to attention the value of S1P receptor antagonists as not only research tools but also potential therapeutic agents.

Introduction

Sphingosine 1-phosphate (S1P) is a pleiotropic lipid signaling mediator that initiates a variety of downstream signaling cascades through its binding and activation of five G protein-coupled receptors (S1P1–S1P5) (Anliker and Chun, 2004). At the cellular level, S1P signaling increases survival, growth, proliferation, intracellular Ca2+ concentration, and rearrangement of the actin cytoskeleton (Pyne and Pyne, 2000; Ishii et al., 2004; Sanchez and Hla, 2004). Knowledge of the in vivo physiological effects of S1P signaling came to the forefront through the discovery and use of FTY720 [fingolimi-
mod; 2-amino-2-(2-[4-octylphenyl][ethyl])-1,3-propanediol), an S1P<sub>R<sub>R<sub>R</sub></sub> receptor agonist prodrug that induces lymphopenia in mice and prolongs the survival of skin transplant allografts (Chiba et al., 1996; Kiuchi et al., 2000; Brinkmann et al., 2002; Mandala et al., 2002; Kihara and Igarashi, 2008). It is now appreciated that S1P receptor stimuli contribute to the modulation of immune cell trafficking, angiogenesis, and heart rate (Spiegel and Milstien, 2003; Haint et al., 2006; Brinkmann, 2007). FTY720 established the value of S1P receptor compounds as not only research tools, but also potential therapeutic agents, given that FTY720 is now a United States Food and Drug Administration-approved drug (Gilenya) for multiple sclerosis (Brinkmann et al., 2010), and other S1P<sub>R</sub> agonists have already been evaluated in clinical trials (Cusack and Stoffel, 2010). Studies have mapped lymphopenia and bradycardia in rodents onto the S1P<sub>1</sub>, and S1P<sub>3</sub> receptors, respectively. For example, a selective S1P<sub>1</sub> agonist (5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl) phenyl]-1,2-oxadiazole; SEW2871) induces lymphopenia (but not bradycardia) in wild-type mice, whereas FTY720 or its phosphorylated analogs fail to produce bradycardia in S1P<sub>3</sub> knockout mice (S1P<sub>R3</sub>−/−) (Forrest et al., 2004; Sanna et al., 2004). These findings provide an impetus to discover more selective compounds that would have greater utility in the elucidation of S1P signaling and potential clinical use.

In addition to receptor-selective agonists such as SEW2871, competitive S1P receptor antagonists have provided insight into the physiological effects of S1P signaling, particularly involving S1P<sub>1</sub>. (R)-3-amino-(3-octylphenylamino)-4-oxobutylphosphonic acid (VPC44116) (S1P<sub>R3</sub> antagonist) and an analog, (R)-3-amino-(3-hexylphenylamino)-4-oxobutylphosphonic acid (W146) (S1P<sub>1</sub> antagonist), both were found to increase capillary permeability as measured by Evans blue dye leakage in mouse lung tissue (Sanna et al., 2006; Foss et al., 2007). It is noteworthy that 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, mono dihydrogen phosphate ester (FTV720-P) has been proposed as a superagonist that acts as a functional antagonist to down-regulate S1P<sub>1</sub> and inhibit both tumor growth and tumor angiogenesis (LaMontagne et al., 2006). In vivo use of S1P<sub>1</sub>-selective small interfering RNA also reduces tumor volume and tumor angiogenesis in mice, further supporting a potential pathological role of S1P<sub>1</sub> in cancer progression (Chae et al., 2004). Several reports have implicated S1P in cancer development (Xia et al., 2000; Akao et al., 2006; Oskouian et al., 2006; Visentin et al., 2006; Pyne and Pyne, 2010; Watson et al., 2010). It has been suggested that an inhibitor of S1P signaling, for example, an S1P<sub>1</sub> receptor antagonist, might have a beneficial dual mode of action by inhibiting hyperproliferative signaling at the cancer cells and angiogenesis at the endothelial cells (Sabadini, 2006). However, such antagonist compounds are scarce, and the pharmacokinetic profiles of the few available have precluded their use in animal models of disease.

We explored the functional chemical space of FTY720 through structure-activity relationship (SAR) studies and discovered a conformationally constrained analog that combines the desirable pharmacokinetic properties of FTY720 with S1P receptor subtype-specific antagonism. Herein we profile this competitive S1P<sub>R</sub> antagonist prodrug, 1-(hydroxymethyl)-3-(3-octylphenyl)cyclobutane (VPC03090). We further assessed lymphopenia and vascular leakage in mice as in vivo physiological indicators of S1P receptor modulation and the ability of VPC03090 to inhibit tumor growth in an immunocompetent mouse mammary cancer model. Although VPC03090 treatment produced no changes in peripheral lymphocyte counts or vascular permeability in mice, it did inhibit the growth of 4T1 syngeneic mouse mammary tumors. Our findings underscore the importance of S1P antagonists as both research tools and aids to the development of new therapeutic scaffolds and drugs.

**Materials and Methods**

**Materials.** Chinese hamster ovary (CHO) cells were obtained from the American Type Culture Collection (Manassas, VA). Genetin (G418 sulfate) and GDP were from Thermo Fisher Scientific (Waltham, MA). Cell culture materials were from Invitrogen (Carlsbad, CA). Charcoal/dextran-stripped fetal bovine serum was purchased from Gemini Bio-Products (Woodland, CA). Sodium orthovanadate, saponin, probenecid, and fatty acid-free bovine serum albumin were from Sigma-Aldrich (St. Louis, MO). S1<sup>33P</sup>, GDP[S<sup>γ</sup>35S], and 96-well GC/F filter plates were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). S1P was from Avanti Polar Lipids (Alabaster, AL). Fluo-4-AM Ca<sup>2+ </sup>fluorophore was from Invitrogen. SEW2871 was from Cayman Chemical (Ann Arbor, MI).

**Animals.** C57BL/6j mice were obtained from The Jackson Laboratory (Bar Harbor, Maine) and handled in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996). S1P<sub>1</sub> null mice, in which the S1P<sub>1</sub> coding exon was replaced by a neomycin selection marker gene cassette, were made under contract with Ingenious Targeting Laboratories (Stony Brook, NY). Embryonic stem cells used to generate these mice were hybrids of both the C57BL/6 and SV129 genetic backgrounds. S1P<sub>1</sub> heterozygote mice were crossed to yield homozygote S1P<sub>1</sub> null offspring. These mice are viable and fertile. All procedures were approved by the Institutional Animal Care and Use Committee of the University of Virginia. Mice used in the 4T1 mammary cancer model were handled according to the rules of Décret 87-848 of Oct. 19, 1987, Paris. This experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the Université Claude Bernard Lyon-1 (Lyon, France). BALB/c mice, 6 weeks of age, were housed under barrier conditions in laminar flow isolated hoods. Autoclaved water and mouse chow were provided ad libitum. Animals bearing tumors were carefully monitored for signs of distress and were humanely euthanized when distress was observed.

**Stable Expression of S1P Receptors in CHO Cells.** pcDNA3.1+ plasmids containing the DNA sequences for each human sphingosine 1-phosphate receptor (S1P<sub>1</sub>−S1P<sub>5</sub>) were obtained from the University of Missouri (Rolla, MO). These plasmids, encoding the amino-terminal triple hemagglutinin-tagged forms of the S1P receptors, as well as ampicillin and neomycin/geneticin resistance, were transfected into CHO cells using Lipofectamine 2000 (Invitrogen). Cells expressing the desired S1P receptor were selected by fluorescence-activated cell sorting in a 96-well format using anti-hemagglutinin-phycoerythrin fluorophore (Milenyi Biotec, Inc., Auburn, CA) and a FACSVantage SE Turbo Sorter (BD Biosciences, Franklin Lakes, NJ). A similar plasmid encoding a GFP-tagged human S1P<sub>1</sub> receptor was used to transfet CHO cells that were then sorted based on GFP fluorescence. Expression of the mouse S1P<sub>1</sub> receptor was achieved by stable transfection of CHO cells using a plasmid containing the mouse S1P<sub>1</sub> expression sequence with an amino-terminal epitope Flag tag in a pcDNA3 vector, followed by similar fluorescence-activated cell sorting using a conjugated anti-Flag fluorescent antibody (Sigma-Aldrich). Isolated clonal populations for each receptor type were maintained under selection by incorporation of 1 mg/ml geneticin (G418) into Ham’s F12 media containing 10% charcoal/dextran-stripped fetal bovine serum, 1% sodium pyruvate, and 1% penicillin and streptomycin solution. Cells were grown at 37°C in a 5% CO<sub>2</sub>/95% air atmosphere.
GTP[γ-35S] Binding Assay. Membranes prepared from CHO cells stably expressing S1P receptors were incubated in 96-well plates in 100 μl of binding buffer (50 mM HEPES, 10 mM MgCl2, and 100 mM NaCl, pH 7.5, containing 0.1% fatty acid-free bovine serum albumin) with 5 μg of saponin, 11.5 μM GDP, 0.3 nM [γ-35S]GTP (1200 Ci/mmol), and a range of S1P or 3-(3-octyloxyphenyl)-1-(phosphono-oxymethyl)cyclobutane (VPC03090-P) concentrations for 30 min at 30°C. Membranes were recovered on GF/C filter plates using a 96-well Brandel Cell Harvester (Brandel Inc., Gaithersburg, MD), and these plates were analyzed for bound radiocuclide using a Top-Count beta scintillation counter (PerkinElmer Life and Analytical Sciences).

S113P] Radioligand Binding Assay. CHO cells stably expressing recombinant S1P receptor types were incubated in 96-well plates in 240 μl of binding buffer (50 mM HEPES, 10 mM MgCl2, and 100 mM NaCl, pH 7.5, containing 0.4% fatty acid-free bovine serum albumin and 1 mM sodium orthovanadate) with various VPC03090-P or S1P concentrations, and 20 pM S113P (3000 Ci/mmol) for 1 h at 4°C. Cells were isolated on GF/C filter plates using a 96-well Brandel Cell Harvester, and filter plates containing cells were analyzed for bound radiocuclide using a TopCount beta scintillation counter (PerkinElmer Life and Analytical Sciences). Background subtraction was performed before software analysis of binding curves.

Determination of the Binding Affinity (Kd or KI) of VPC03090-P for the S1P Receptors. Data from the GTP[γ-35S] binding assay were analyzed using a sigmoidal dose-response non-linear regression model in Prism software (GraphPad Software, Inc., San Diego, CA) to produce EC50 values. Dose ratios were calculated as the ratio between the IC50 values for agonists in the presence and absence of antagonist VPC03090-P. Schild regression analysis was performed by plotting log(dose ratio − 1) versus log antagonist concentration and finding the KI value from the antilog of the x-intercept of the line of best fit. S113P radioligand binding curve data were analyzed by nonlinear regression in Prism software to ascertain IC50 values. KI (or KD for VPC03090-P as agonist) values were determined from IC50 values using the Cheng-Prusoff equation: KI = IC50/(1 + (radioligand concentration/affinity of radioligand for receptor)), where the radioligand concentration of S113P was 20 nM (Cheng and Prusoff, 1973).

Western Blotting. CHO cells stably transfectted to express recombinant human S1P1 were cultured and grown to confluence on 100-mm plates in Ham’s F12 media containing 10% charcoal/dextran-stripped fetal bovine serum, 1% sodium pyruvate, 1% penicillin and streptomycin solution, and 1 mg/ml geneticin. The cells were detached with a scraper, harvested in ice-cold phosphate-buffered saline (PBS), collected by centrifugation, and resuspended in cell lysis buffer [50 mM Tris, pH 8.0, 125 mM NaCl, 20 mM CHAPS, 2 mM dithiothreitol, 1 mM EDTA, 2 mM sodium vanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN)]. Cells were lysed by repeated passage through a 28-gauge needle. The cell lysis homogenate was centrifuged to collect the supernatant. Protein concentration of the supernatant fluid was determined by bicinchoninic acid protein assay (BCA protein assay; Pierce, Rockford, IL). Membranes, bound proteins were detected using the following antibodies: anti-phospho-Akt, rabbit monoclonal antibody to phospho-Akt (Cell Signaling Technology); anti-p-ERK1/2, rabbit polyclonal antibody to Akt, and rabbit polyclonal antibody to ERK1/2. We assessed equal protein loading using a β-actin antibody (Cell Signaling Technology). Detection was achieved using a goat anti-rabbit secondary antibody conjugated to an IRDye 800 CW infrared dye (LI-COR Biosciences, Lincoln, NE). The blot was digitally imaged in an Odyssey Infrared Imaging unit (LI-COR Biosciences), and signal intensity of the detected bands was quantified using Odyssey Imaging Software version 3.0 (LI-COR Biosciences).

Intracellular Ca2+ Mobilization assay. CHO cells expressing either hS1P2 or hS1P3 were plated in 96-well, clear-bottom, black-well microplates (Corning Life Sciences, Lowell, MA) and grown overnight to confluence. The cells were washed with 1× PBS and loaded with the Ca2+ indicator Fluo-4 by incubation in a solution containing 1.8 μM Fluo-4AM ester, 4.5 mM NaOH, and 2.5 mM propranolol in a loading buffer of Hank’s balanced salt solution, initial pH 6.4, containing 20 mM HEPES and 0.1% fatty acid-free bovine serum albumin. After incubation in this solution for 30 min at 37°C, the cell monolayers were washed three times with PBS, and Hank’s balanced salt solution was added. Ca2+ signals were measured as a function of fluorescence in response to compound addition within a FLEXStation (Molecular Devices, Sunnyvale, CA).

Liquid Chromatography-Mass Spectrometry Quantification. Biological samples were extracted using a protocol modified from that of Shaner et al. (2009). Plasma samples (100 μl) were added to glass vials containing 1 ml of 3:1 methanol/chloroform solution. After addition of 2 μl of an internal standard solution containing 20 μM 1-(hydroxymethyl)-3-(3-nonaphenyl)cyclobutane (VPC03099) (a C9 analog of VPC03090) and 2 μM 3-(3-heptylphenyl)-1-(phosphono-oxymethyl)cyclobutane (VPC03093) (a C7 analog of VPC03090-P), the samples were vortexed and then sonicated for 10 min in a water-bath sonicator. The samples were incubated overnight at 48°C, allowed to cool, and then supplemented with 100 μl of 1 M potassium hydroxide in methanol, followed by vortexing and sonication for 10 min. After a 2-h incubation at 37°C, 10 μl of glacial acetic acid was added, and then the samples were transferred to Eppendorf tubes and centrifuged at 10,000g for 10 min at 4°C. The supernatant was transferred to glass vials and dried under a nitrogen stream. Dried samples were then reconstituted in 20 μl of liquid chromatography-mass spectrometry (LC-MS)-grade methanol, vortexed, and centrifuged in Eppendorf tubes at 12,000g for 12 min at 4°C. Forty-microliter samples of the supernatant were analyzed by LC-MS using a Shimadzu UFLC High-Performance Liquid Chromatograph (Shimadzu Scientific Instruments, Columbia, MD) equipped with an EC 125/2 Nucleodur C8 Gravity 5-μm column (125 mm) (Macherey-Nagel, Bethlehem, PA) connected to a AB 4000 QTRap triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA). Chromatography was carried out at room temperature using 10% methanol, 90% water as solvent A, and 90% methanol, 10% water as solvent B. Both solvents were supplemented with 0.1% formic acid and 5 mM ammonium formate. Total flow was 0.33 ml/min. and the following gradient was used: 100% solvent A for 5 min, followed by a linear gradient from 0% to 90% solvent B for 6 min, and 100% solvent B for 2 min. Retention times were between 5 and 6 min. Analyte detection was carried out using the following transitions in positive mode under optimal voltages for each analyte: 290.2 → 255.2 and 290.2 → 143.0 (VPC03090); 370.2 → 272.2 and 370.2 → 82.0 (VPC03090-P); 304.3 → 143.1 and 304.3 → 157.1 (VPC03099, C9 analog of VPC03090); 356.2 → 258.1 and 356.2 → 82.0 (VPC03093, C7 analog of VPC03090-P). The mass spectrometry parameters were as follows: curtain gas, 2; collision gas, medium; ionspray voltage, 5500; temperature, 550; ion source gas 1, 10; ion source gas 2, 0; declustering potential, 76; entrance potential, 10. Peak areas for analytes VPC03090 and VPC03090-P were determined based on integration of peak areas and corrected for recovery using the internal standards. Molar concentration of the analytes in biological samples was obtained from a standard curve. A standard curve was run for each experiment.

Lymphopenia Assessment. Mice were dosed with compound (as indicated in the figures) dissolved in water containing 2% hydroxypropyl β-cyclodextrin (Cargill, Inc., Cedar Rapids, IA). Blood was collected from the orbital sinus of lightly anesthetized mice. Periphi-
eral lymphocytes were counted using a Hemavet 950 blood analysis unit (Drew Scientific, Oxford, CT) calibrated for mouse blood.

4T1 Mouse Mammary Cancer Model. Mouse 4T1 breast cancer cell lines (syngeneic on BALB/c genetic background) were obtained from the American Type Culture Collection and cultured in complete Dulbecco’s modified Eagle’s medium (Invitrogen), 10% (v/v) fetal bovine serum (Perbio Science UK Ltd., Chester, Cheshire, UK), and 1% penicillin/streptomycin (Invitrogen), at 37°C in a 5% CO2, 95% air atmosphere. Tumor fat pad experiments were performed by injecting 4T1 cells (106 in 10 μl of PBS) injected into the fat pad of the fourth mammary gland of female BALB/c mice of 6 weeks of age (Charles River Breeding Laboratories, Portage, MI) as described previously (David et al., 2010). Animals were treated from day 1 until day 14 with VPC03090 (6.2 mg/kg/day) by intraperitoneal injection. Fourteen days after tumor cell injection, animals were sacrificed and primary tumors were collected. Tumor volumes were determined using a Vernier caliper. Tumor volume (TV; expressed in mm3) was calculated using the following equation: TV = (length × width2)/2.

Statistical Analysis. Binding curve and concentration-response data were analyzed by nonlinear regression with a sigmoidal dose-response fit model in Prism software to yield IC50 or EC50 values and their associated 95% confidence intervals. Peripheral lymphocyte count data were analyzed in Prism where indicated by Student’s t test or one-way analysis of variance (ANOVA) as appropriate. Additional details on statistical analysis can be found in the figure legends.

**Results**

**Effect of VPC03090-P on S1P Receptor Activity.**

Through an investigation into the chemical space surrounding the sphingosine analog FTY720 (Fig. 1), we generated a conformationally constrained analogous compound in which the aryl substituent of FTY720 was changed from para to meta, and the ethyl linker was modified to a cyclobutyl ring. We designated this compound VPC03090 (Fig. 1). The phosphorylated form of VPC03090 (VPC03090-P) was also synthesized (Fig. 1), as were alcohol and phosphorylated species of analogs where the length of the alkyl hydrocarbon group ranged from 7 to 10 carbon atoms.

The effect of VPC03090-P on all five S1P receptor subtypes was assessed in a GTP[γ-35S] binding assay as shown in Table 1. We observed inverse agonism with hS1P1 and hS1P3 receptors suggesting antagonism by VPC03090-P at these receptors. VPC03090-P produced concentration-dependent, parallel rightward shifts in the S1P agonist concentration-effect curve at human S1P1 (Fig. 2A), mouse S1P1 (Fig. 2B), and human S1P3 (Fig. 2C), which is consistent with the compound being a competitive antagonist. Analysis of EC50 best-fit and confidence interval linear regression data found that for hS1P1 and hS1P3 100 nM VPC03090-P evoked a significant shift in S1P potency at the receptor. Treatment with 1 μM VPC03090-P significantly shifted the EC50 value of S1P by one log order at hS1P1, mS1P1, and hS1P3.

We determined VPC03090-P antagonism to be S1Pm-selective through the results obtained from the other S1P receptors. VPC03090-P demonstrated agonist activity at hS1P4 and hS1P5. Specifically, VPC03090-P was more potent and efficacious than S1P at hS1P4 (Supplemental Fig. 1A). The EC50 values for S1P and VPC03090-P (56 and 17.7 nM, respectively) were significantly different, and the Emax of VPC03090-P relative to S1P was 1.7. At hS1P5, VPC03090-P was equally potent but less efficacious than S1P (Supplemental Fig. 1B). Respective EC50 values of 4.4 and 2.4 nM for S1P and VPC03090-P were not significantly different. The Emax of VPC03090-P relative to S1P was 0.26. VPC03090-P exhibited neither agonism nor antagonism at hS1P2 in a Ca2+ mobilization assay. The presence of the phosphate group seemed necessary for activity at S1P1/3/4/5, because VPC03090 (the nonphosphorylated form) lacked significant activity at these receptors for concentrations up to 10 μM in the GTP[γ-35S] binding assay (data not shown).

To determine receptor specificity further, we screened VPC03090-P at members of a closely related family of receptors, the lysosphatidic acid (LPA) receptors. VPC03090-P was devoid of activity at LPA1 and LPA3 at concentrations up to 10 μM in the GTP[γ-35S] binding assay (data not shown).

**Affinity of VPC03090-P for S1P Receptors.** Dose ratios were determined from shifts in S1P EC50 values produced by VPC03090-P antagonism at receptors S1P1 and S1P5 in the GTP[γ-35S] binding assay (Fig. 2). A Schild regression analysis of these data yielded the following Ki values: 24 nM (hS1P1), 14 nM (mS1P1), and 51 nM (S1P5). As an independent test of these affinity measurements, a whole-cell radioligand binding assay was performed using CHO cells overexpressing each particular S1P receptor subtype. Binding was measured as the amount of tracer S1[33P] bound to the cells in the absence or presence of competitor, either nonradiolabeled S1P or VPC03090-P. The Ki or Kd value was determined using the Cheng-Prusoff equation, and the IC50 values were obtained from the radioligand binding displacement curves. The VPC03090-P affinity constant values obtained by radioligand binding studies closely mirror EC50 values de-
TABLE 1

Characterization of VPC03090-P as a ligand for the different subtypes of the S1P receptor.

VPC03090-P binding parameters for recombinant mS1P1 and hS1P1–5 receptors. Activity of VPC03090-P at the S1P receptor was determined from a GTPγS binding assay carried out using membranes prepared from CHO cells expressing each of the S1P receptor subtypes separately (except S1P3). Elevated levels of bound GTPγS in response to increasing VPC03090-P concentrations were designated as agonist activity, whereas a rightward shift in the concentration-response curve of S1P upon coapplication of VPC03090-P at a fixed concentration was designated as antagonist activity. EC50 values were determined by nonlinear regression analysis from a sigmoidal dose-response curve fit of VPC03090-P concentration-response data. In the case of antagonism, KI values were obtained by Schild Regression analysis of GTPγS assay data as described under Materials and Methods. Affinity values (Ki or KI) were independently determined from the Cheng-Prusoff calculation using IC50 values obtained in a radioligand binding assay as detailed under Materials and Method. S1P1 receptor activity in response to VPC03090-P was evaluated using a Ca2+ mobilization assay.

<table>
<thead>
<tr>
<th>S1P Receptor</th>
<th>VPC03090-P Activity</th>
<th>EC50 (nM)</th>
<th>% Inhibition Relative to S1P</th>
<th>KI from Schild Regression (nM)</th>
<th>KI from Radioligand Binding (nM)</th>
<th>KI from Radioligand Binding (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mS1P1</td>
<td>Antagonist</td>
<td>N.A.</td>
<td>N.A.</td>
<td>14</td>
<td>21.3</td>
<td>N.A.</td>
</tr>
<tr>
<td>hS1P1</td>
<td>Antagonist</td>
<td>N.A.</td>
<td>N.A.</td>
<td>24</td>
<td>21</td>
<td>N.A.</td>
</tr>
<tr>
<td>hS1P3</td>
<td>No activity</td>
<td>N.A.</td>
<td>N.A.</td>
<td>51</td>
<td>58.7</td>
<td>N.A.</td>
</tr>
<tr>
<td>hS1P2</td>
<td>Antagonist</td>
<td>N.A.</td>
<td>N.A.</td>
<td>1.7</td>
<td>N.A.</td>
<td>17.3</td>
</tr>
<tr>
<td>hS1P3</td>
<td>Agonist</td>
<td>17.7</td>
<td>1.7</td>
<td>N.A.</td>
<td>N.A.</td>
<td>2.3</td>
</tr>
<tr>
<td>hS1P2</td>
<td>Partial agonist</td>
<td>2.4</td>
<td>0.26</td>
<td>N.A.</td>
<td>N.A.</td>
<td>N.A.</td>
</tr>
</tbody>
</table>

N.A., not applicable.

We next compared the potency of VPC03090-P to that of other S1P receptor antagonists by examining the 95% confidence intervals for the EC50 value of S1P in the presence of 1 μM antagonist. VPC03090-P was indistinguishable in potency compared with VPC44116 (Fig. 1) at S1P1, whereas at S1P2, VPC03090-P was significantly more potent than (R)-phosphoric acid mono-[2-amino-2-(3-octyl-phenylcarbamoyl)-ethyl] ester (VPC23019) (Fig. 1), VPC44116, and W146 (Fig. 1) (data not shown). Comparison of S1P receptor antagonist affinities at all of the S1P receptors is provided in Supplemental Table 1.

Influence of VPC03090-P on S1P Receptor Signaling. Next, we investigated whether VPC03090-P behaves as an antagonist of S1P receptor function. Prompted by previous observations that S1P signaling promotes downstream enhancement of phosphatidylinositol 3-kinase activity and phosphorylation of Akt and ERK (Pyne and Pyne, 2000; Ishii et al., 2004) and the S1P1-selective antagonist W146 inhibits S1P- or SEW2871-induced phosphorylation of Akt and ERK in CHO cells expressing hS1P1 (Sanna et al., 2006), we determined the effect of VPC03090-P on ERK1/2 phosphorylation. Using a whole-cell assay consisting of CHO cells expressing hS1P1, we found that both S1P and SEW2871 induced significant phosphorylation of ERK1/2 in the presence of vehicle, yet this ERK1/2 phosphorylation was significantly inhibited in the presence of VPC03090-P (Fig. 3, A and B). We observed a similar trend in S1P- or SEW2871-evoked Akt phosphorylation, which was also inhibited in the presence of VPC03090-P (not shown). No significant difference was found between levels of ERK1/2 phosphorylation in the presence of vehicle alone versus VPC03090-P alone.

We examined the effect of VPC03090-P on S1P1 receptor function by taking advantage of the fact that the S1P1 receptor couples to Gq to influence inositol triphosphate formation and mobilization of Ca2+ from intracellular stores (Ishii et al., 2004). Specifically, we investigated changes in intracellular Ca2+ in CHO cells expressing the S1P3 receptor.

We found that VPC03090-P significantly decreased the potency of S1P as a promoter of intracellular Ca2+ mobilization (Fig. 3C). Addition of 1 μM VPC03090-P significantly shifted the EC50 value for S1P in this assay by more than one log order. VPC03090-P alone produced no change in intracellular Ca2+ signal in agreement with the lack of positive efficacy of VPC03090-P at the S1P3 receptor observed in our broken cell assays.

Pharmacokinetic Parameters of VPC03090 in Mice. The structural similarity between VPC03090 and PTV720 (Fig. 1) suggested that VPC03090 could also be a substrate for sphingosine kinases. Accordingly, in vitro testing with recombinant sphingosine kinases revealed that VPC03090 was a substrate for both human and mouse sphingosine kinase 2 (Km = 23 μM) but not sphingosine kinase 1 (Yuges Kharel and Kevin Lynch, unpublished observations). These observations prompted us to establish a quantitative LC-MS method for measuring levels of VPC03090 and VPC03090-P in plasma from mice that were administered VPC03090.

Plasma levels in mice 16 h after a single 10 mg/kg i.p. dose of VPC03090 were as follows: 860 nM (± 142 nM) VPC03090-P and 568 nM (± 79.7 nM) VPC03090 (n = 5). We next assessed oral availability and duration of VPC03090 in mice after a single dose of VPC03090 (10 mg/kg) delivered by oral gavage. Our results demonstrate that VPC03090 is rapidly phosphorylated in vivo. As Fig. 4 illustrates, VPC03090-P appears in plasma within 30 min (our earliest time point). The approximate phosphorylated/alcohol species ratio of 1:1 that was found at 30 min persisted for 6 days after a single dose (Fig. 4), revealing an in vivo interconversion between VPC03090 and VPC03090-P. Using an exponential decay model, we determined the half-life of VPC03090-P in these mice to be 30 h.

To ascertain which sphingosine kinase is responsible for the phosphorylation of VPC03090 in vivo, we treated sphingosine kinase 2 null mice with VPC03090 (30 mg/kg i.p.) and analyzed plasma samples obtained 15 h after dosing. In this case, we found that plasma VPC03090 concentrations were in the micromolar range, but we failed to detect VPC03090-P, indicating that VPC03090-P was either absent or existed at concentrations below the limit of detection of our LC-MS method (approximately 2.5 nM) (data not shown; n = 4). We were also unable to detect VPC03090-P in plasma at longer time points, 2 and 4 days, after a single 10 mg/kg i.p. dose of VPC03090 (data not shown). These experiments demonstrate...
that in vivo phosphorylation of VPC03090 occurs mostly, if not exclusively, via sphingosine kinase 2. Unfortunately, we were unable to test this hypothesis using higher doses of VPC03090 because VPC03090 was found to be lethal at doses more than 30 mg/kg i.p. We also found that the lethal dose of VPC03090 for sphingosine kinase 2 null mice is approximately similar to that for wild-type animals of the same genetic background. This suggests that the alcohol form is responsible for this effect because according to our measurements sphingosine kinase 2 null mice are unable to phosphorylate VPC03090.

Modulation of S1P<sub>1</sub> Activity In Vitro and In Vivo by Alteration of Alkyl Chain Length. We synthesized VPC03090-P analogs in which the alkyl chain was seven (C7), nine (C9), or 10 (C10) carbon atoms to analyze the SAR for this part of the VPC03090-P molecule. In vitro analysis of activity at the S1P<sub>1</sub> receptor revealed EC<sub>50</sub> values of 10, 30, and 178 nM for S1P, C10-P analog, and C9-P analog, respectively. Moreover, the VPC03090-P analogs exhibited different efficacy at S1P<sub>1</sub>. The seven-carbon (C7) and eight-carbon (C8) hydrocarbon chain analogs showed negative or neutral efficacy, whereas installation of the C9 chain presented positive efficacy/agonism that was exaggerated in the C10 analog (Fig. 5A). The E<sub>max</sub> values (relative to S1P) for the C9 and C10 compounds were 0.09 and 0.27, respectively. This trend of increasing efficacy at S1P<sub>1</sub>, with increased alkyl chain length had been previously observed for our original S1P receptor antagonist series of alkyl phenyl amide compounds that included VPC23019 (Davis et al., 2005).

A well established biomarker of S1P<sub>1</sub> agonism is lymphopenia, a reduction of peripheral lymphocytes resulting from their sequestration in secondary lymphoid organs (Brinkmann et al., 2002; Mandala et al., 2002; Forrest et al., 2004; Sanna et al., 2004). In agreement with our in vitro analysis of phosphorylated analog efficacy at S1P<sub>1</sub>, the C10 analog of VPC03090 significantly lowered peripheral lymphocyte counts in mice (Fig. 5B), indicating that this analog is also a prodrug, presumably activated by sphingosine kinase 2, as is the case for VPC03090 and FTY720. Although slight positive efficacy was observed in the GTP<sup>γ-35S</sup> assay for the C9 analog, no significant lymphopenia was evoked by this compound at 16 h after a 10 mg/kg i.p dose (data not shown). This suggests that the lymphopenia only occurs above a threshold of positive agonism at the S1P<sub>1</sub> receptor that lies somewhere between that of the C9 and C10 analogs. The C8 compound VPC03090 produced no significant changes in peripheral lymphocyte counts over a dose range of 1 to 15 mg/kg i.p. in mice (Fig. 5C). In these same mice, VPC03090-P levels increased with dose escalation of VPC03090, and the VPC03090-P concentration achieved in plasma was well above the K<sub>i</sub> value (21 nM) for the S1P<sub>1</sub> receptor (data not shown).

No significant inhibition of SEW2871-induced lymphopenia was produced by coadministration of VPC03090 in wild-type mice (data not shown). We sought to effectively rule out any potential interference in vivo from VPC03090-P-induced S1P<sub>4</sub> agonism in our attempt to observe inhibition of lymphopenia. We performed the lymphopenia assay in mice null for S1P<sub>4</sub> and found that (similar to results in wild-type mice) VPC03090 neither induced lymphopenia alone, nor reversed...
VPC03090 antagonism of S1P₁ influence over lymphocyte trafficking.

Assessment of Effects on Mouse Lung Endothelial Vascular Integrity. Alkyl phenyl amide phosphonate S1P₁ antagonists have been shown to compromise vascular integrity of mouse lung endothelium, leading to extravasation of Evans blue dye into lung tissue (Sanna et al., 2006; Foss, et al., 2007). We therefore tested whether VPC03090, which is based on a different chemical scaffold, would produce a similar effect and provide support to the contention that S1P₁ antagonism adversely affects the integrity of endothelial barriers. However, we were unable to induce any significant vascular leakage by the use of VPC03090 or VPC03090-P, despite having tested various doses, routes of administration, and exposure times (data not shown).

These negative results prompted us to test the hypothesis that the lack of VPC03090- (or VPC03090-P)-evoked vascular leakage was perhaps caused by the opposing effects of potent S1P₃ receptors in the mod-

---

Fig. 3. Inhibition of signaling targets downstream of S1P receptors. A, Western blot to detect phosphorylation state of ERK1/2 in CHO cells expressing human S1P₃. Cells were serum-starved for 16 h, then incubated with 10 µM VPC03090-P or vehicle for 1 h, and then stimulated where indicated by 100 nM S1P or 1 µM SEW2871 for 5 min. A standardized protein amount of 128 µg was loaded in all lanes. The experiment was performed in duplicate for all conditions with representative results shown here. B, quantification of signal intensity for pERK1/2 bands detected on Western blot. Signal intensity of phosphorylated ERK1/2 protein bands detected by infrared imaging as described under Materials and Methods was quantified using Odyssey Infrared Imaging software (LI-COR, Inc.) and presented here in arbitrary units. Each column bar represents the average of a duplicate, and error bars depict the S.E.M. Results were analyzed for statistical significance within Prism software by performing a one-way ANOVA test, followed by a Newman-Keuls multiple comparison post-test. **, p < 0.01 for VPC03090-P + 100 nM S1P versus VPC03090-P + 1 µM SEW2871 comparison. ***, p < 0.001 for vehicle + 100 nM S1P versus vehicle comparison, and separately, vehicle + 1 µM SEW2871 versus vehicle comparison. C, results from a Ca²⁺ mobilization assay using CHO cells expressing human S1P₃. Relative fluorescence units (RFU) indicate the amount of fluorescence produced from a Ca²⁺-sensing fluorophore in response to a concentration range of applied S1P, VPC03090-P, or coapplication of S1P and a fixed concentration of VPC03090-P. Each data point represents the average of a quadruplicate, with the error bars indicating the S.E.M.

---

Fig. 4. Quantification of VPC03090 and VPC03090-P levels from mouse plasma over time after an oral dose of VPC03090. Data points shown depict the average concentrations (molarity) of VPC03090 (○, dashed line) and VPC03090-P (■, solid line) in mouse plasma at 30 min (0.5 h), 2 days (48 h), 4 days (96 h), and 6 days (144 h) after a single oral dose (10 mg/kg) of VPC03090 to wild-type C57BL/6 mice. Error bars represent S.D. (n = 5 for all points except n = 4 for 144-h time point). Quantification of VPC03090 and VPC03090-P was performed by LC-MS as described under Materials and Methods.

---

the lymphopenia evoked by the S1P₃-selective agonist SEW2871 (Supplemental Fig. 2A). Thus, activation of S1P₃ does not seem to be contributing to the lack of detectable vascular leakage at the same dose and route of administration in S1P₃.
null mice. Whereas VPC44116 produced significant vascular leakage in these S1P$_4^\text{−/−}$ mice, VPC03090-P did not (data not shown). We further considered the possibility that perhaps agonism at S1P$_4$ evoked by VPC03090-P in vivo might interfere with the manifestation of vascular leakage. To test this hypothesis, we used S1P$_4$ null mice that are devoid of this particular receptor. In the S1P$_4$ null mice, VPC44116 evoked significant extravasation of EBD into lung tissue compared with treatment with either vehicle or VPC03090-P (Supplemental Fig. 2B). As had been previously observed in wild-type and S1P$_4$ null mice, VPC03090-P did not induce any significant vascular leakage compared with vehicle in the S1P$_4$ null mice (Supplemental Fig. 2B). These data effectively rule out the possibility of prevention of vascular leakage by VPC03090-P agonism at S1P$_4$.

**Impact of VPC03090 on Tumor Growth.** Given the prosurvival, promigratory, and mitogenic effects of S1P, we hypothesized a possible beneficial effect of VPC03090 in pathological conditions where hyperproliferation plays a central role. To this end, we tested the antitumor efficacy of this molecule in two aggressive, immunocompetent mouse cancer models: Lewis lung carcinoma and 4T1 mammary carcinoma.

For the Lewis lung carcinoma model, we devised a dosing scheme that would sustain drug levels equivalent to an average dose of 10 mg/kg p.o. daily over the duration of the tumor model. This dosing scheme consisted of an initial loading dose of 13 mg/kg p.o., followed by a maintenance dose of 5.5 mg/kg p.o. every 24 h. The maintenance value was meant to compensate for the daily loss calculated using the half-life obtained in the experiment shown in Fig. 4. We chose 10 mg/kg p.o. as a daily dose because it is apparently well tolerated and provides VPC03090-P drug levels of more than 10-fold the $K_i$ at the S1P$_1$ receptor (Fig. 4 and Table 1). The described dosing regimen was initiated once syngeneic subcutaneous Lewis lung carcinoma tumors had become palpable in the flank of C57BL/6 mice. An analysis of tumor volume over 2 weeks of daily treatment found that VPC03090 did not significantly inhibit tumor growth in this model (data not shown).

In the 4T1 mammary cancer model, a dosing scheme of 6.2 mg/kg/day i.p. of VPC03090 was used. VPC03090 significantly reduced tumor volume in this model. As shown in Fig. 6, median tumor volume was reduced approximately
3-fold by VPC03090 treatment compared with vehicle treatment.

**Discussion**

S1P receptor antagonists are desirable as tools to probe S1P biology and are necessary to learn whether blockade of S1P signaling at the receptor level might be a viable therapeutic strategy. Since the introduction of FTY720 (Fig. 1), a S1P receptor pan agonist prodrug now in clinical use (Brinkmann et al., 2010), numerous studies have focused on obtaining FTY720 analogs with improved potency and/or selectivity. In this study we present VPC03090, an FTY720 analog that combines selective S1P receptor antagonism with similar pharmacokinetic characteristics to FTY720. We were guided by our previous studies on the SAR of FTY720-P that yielded the first S1P<sub>1,3</sub> receptor antagonist, VPC23019 (Davis et al., 2005). The conformationally constrained VPC23019 (Fig. 1) proved to be short-lived in vivo, presumably because of rapid dephosphorylation (Lynch and Macdonald, 2008). Its phosphonate analog VPC44116 (Fig. 1) (Foss et al., 2007), however, persists longer in rodents (T<sub>1/2</sub> = 2–3 h) and a shorter chain (C6 versus C8) version, W146 (Fig. 1), has increased S1P<sub>1</sub> selectivity (Sanna et al., 2006). These molecules, which are inverse agonists in GTP<sup>•</sup>/H<sub>9253</sub>/H11022 binding assays, have double-digit nanomolar affinities for human and mouse S1P<sub>1</sub> receptors (Supplemental Table 1).

VPC03090 was built on the FTY720 scaffold, but incorporates a crucial structural feature of the VPC23019 series, installation of the alkyl group meta rather than para as in FTY720. We had found previously that conversion of the phenyl ethyl moiety in FTY720 to phenyl cyclopentyl resulted in a long-lived, orally available S1P prodrug that was an S1P<sub>1</sub> agonist and S1P<sub>3</sub> antagonist (1-[1-amino-3-(4-octylphenyl)cyclopentyl]methanol; VPC01091) (Zhu et al., 2007). Thus our strategy to avoid another essential feature of the VPC23019 molecule, i.e., the requirement of <i>s</i> configuration of the amino carbon (which precludes recycling of the alcohol species by reporphosphorylation as in FTY720), was solved by conversion of the phenyl ethyl “linker” in FTY720 to phenyl cyclobutyl. The resulting amino alcohol, VPC03090, combines the dual S1P<sub>1,3</sub> antagonist (and S1P<sub>4,5</sub> agonist) properties of the lead antagonist VPC23019 with the prodrug/active drug (alcohol/phosphate) cycling of FTY720 and thereby captures the oral availability and in vivo longevity of the latter compound.

We anticipate that VPC03090 can be used to investigate the in vivo consequences of long-term S1P<sub>1,3</sub> antagonism. Pharmacodynamic studies of the shorter-lived antagonists VPC44116 and W146 in mice have yielded two salient results. First, they do not induce lymphopenia (Sanna et al., 2006; Foss et al., 2007) in discrepancy with the proposed “functional antagonist” mechanism of S1P<sub>1</sub> agonist-driven lymphopenia (Matloubian et al., 2004). Second, they induce pulmonary vascular leakage (Sanna et al., 2006; Foss et al., 2007), which supports the notion that circulating S1P (Hammad et al., 2010) tonically supports endothelial barrier function via S1P<sub>1</sub> receptor activation (Marsolais and Rosen, 2009). When we administered VPC03090 to mice, we observed neither changes in circulating lymphocyte counts nor leakage of Evans blue dye.

An explanation proffered for failure of S1P<sub>1</sub> antagonists to drive lymphopenia is that these molecules are not potent enough (Pappu et al., 2007). VPC03090-P, which is nearly equipotent to other S1P antagonists at S1P<sub>1</sub> (Supplemental Table 1), might also be insufficient in this regard, even though the trough plasma levels were well into the triple-digit nanomolar range. The failure of VPC03090 to block lymphopenia driven by the S1P<sub>1</sub>-selective agonist, SEW2871, supports this argument. We also considered the explanation that VPC03090-P might be highly bound to plasma proteins and thus the concentration available to the S1P<sub>1</sub> receptor would be correspondingly low. However, this thinking is belied by the lymphopenia observed in response to the equipotent S1P<sub>1</sub> agonist C10 analog of VPC03090, which would seem to be no less protein bound than the C8 VPC03090. We observed neither lymphopenia nor lymphopenia inhibition from VPC03090 in S1P<sub>1</sub> null mice, excluding any potential confounding effect from agonism at this receptor.

The lack of vascular leakage in response to VPC03090-P seems more curious. Although we have never failed to observe pulmonary leakage of Evans blue dye in response to VPC44116 in mice (2–20 mg/kg i.v. i.p.; <i>n</i> > 20), we have not observed it in any VPC03090 (10 mg/kg i.p.)- or VPC03090-P (10 mg/kg i.p.; 2 mg/kg i.v.)-treated mice (<i>n</i> > 12). These VPC03090 and VPC03090-P dosing regimens produce concentrations of VPC03090-P in mouse plasma far in excess of its <i>K</i><sub>i</sub> value at mouse S1P<sub>1</sub> (21 nM). We considered that either the agonist activity of VPC03090-P at S1P<sub>4</sub> or the antagonist activity of VPC03090-P at S1P<sub>3</sub> might have counterbalanced the effects of S1P<sub>1</sub> antagonism, preventing vascular leakage. However, we did not observe vascular leakage in either S1P<sub>4</sub> null mice or S1P<sub>3</sub> null mice in response to VPC03090-P, which compels us to consider the possibility that the vascular leakage observed in mice treated with VPC44116 (or its C6 congener W146) is not a consequence of S1P<sub>1</sub> blockade, but rather an off-target effect of compounds with the phenyl amide scaffold. Unfortunately, deletion of the S1pr1 gene is embryonically lethal, thus the genetically altered mice that would provide greater clarification of this issue are not available (Liu et al., 2000). Discovery of S1P<sub>1</sub>-selective antagonists with in vivo stability and alternative scaffolds are called for in resolving the discrepancy in the vascular leakage phenomenon.

Numerous reports have suggested a pathological role for aberrant S1P metabolism and signaling in carcinogenesis (Xia et al., 2000; Akao et al., 2006; Oskouian et al., 2006; Pyne and Pyne, 2010; Watson et al., 2010). Indeed, S1P signaling through receptors stimulates potentially cancerous signaling through receptors stimulates potentially cancerous processes (Pyne and Pyne, 2000; Ishii et al., 2004). It has been proposed that S1P may be signaling at two sites concurrently to perpetuate tumor growth: 1) S1P receptors on the cancer cell to promote survival, proliferation, migration, and proangiogenic cytokine release, and 2) S1P<sub>1</sub> on the vascular endothelial cell to evoke local angiogenesis (Sabbadini, 2006). As evidence, an anti-S1P antibody reduced endothelial cell migration, cancer cell migration, proliferation, invasion, and tumor angiogenesis and inhibited tumor growth for several different cancer types (Visentin et al., 2006). Furthermore, S1P<sub>1</sub> has been demonstrated to participate in a positive-feedback mechanism with signal transducer and activator of transcription 3 to promote progression of cancer malignancy (Lee et al., 2010). Down-regulation of S1P<sub>1</sub>
through pharmacological tools or small interfering RNA has been shown to decrease angiogenesis and tumor growth (Chae et al., 2004; LaMontagne et al., 2006). As a logical extension of published evidence, we conclude that an S1P1 antagonist should also provide an advantageous dual mode of action. Even if a cancer cell exhibits reduced dependence on S1P1 signaling for survival as a result of a mutation, tumor growth would still be restricted by insufficient nourishment because of the antiangiogenic effect of S1P1 antagonism. Moreover, the specificity provided by an S1P1/3 receptor antagonist might be more beneficial than a nonspecific sphingosine kinase inhibitor or SIP1 antibody.

In view of the potency/affinity, bioavailability, and in vivo longevity of the S1P1 antagonist prodrug VPC03090, we assessed its effectiveness for tumor growth inhibition in two mouse cancer models. The first was an ectopic Lewis lung carcinoma model in which treatment is initiated once tumors are detected by palpation. Measurements of subcutaneous tumor volume over time revealed no significant differences between vehicle- and VPC03090-treated animals. Unfortunately, we observed large deviations in tumor size in both groups, which would have prevented us from detecting an effect had there been one. Our second model was an orthotopic immunocompetent 4T1 mammary cancer model in which treatment begins the same day that cancer cells are injected into the mammary gland. In this setting, VPC03090 significantly reduced tumor volume. Several possibilities may account for the differences in efficacy between the tumor models. The 4T1 cells may depend more heavily on SIP signaling for survival or angiogenesis or may exhibit this dependence in earlier phases of tumor growth. Both tumor models shared a similar duration of treatment, but the 4T1 model initiated treatment at an earlier phase of carcinogenesis. We further speculate that perhaps the difference in tumor placement between the two models may have resulted in a greater delivery of systemic VPC03090 or VPC03090-P to the mammary tumor versus a subcutaneous tumor. Nevertheless, our finding warrants further investigation using VPC03090 and other drug-like SIP1 antagonists in additional cancer models.

The high degree of similarity between the mouse and human SIP1 receptor coupled with the similar antagonism and binding affinity of VPC03090-P at both mouse and human SIP1 supports the possibility for translational research in the context of SIP-driven malignant neoplasia. VPC03090 is also a substrate for both mouse and human sphingosine kinase type 2. The translational potential is underscored by the history of FTY720, a SIP1 receptor prodrug agonist that is now a United States Food and Drug Administration-approved treatment for multiple sclerosis (Brinkmann et al., 2010). We anticipate that VPC03090 will inform future SAR studies, provide incentive for further SIP receptor antagonist discovery, and be useful in validation of the SIP receptors as drug targets. SIP receptor antagonists hold dual promise as research tools and potential therapeutic agents in the ongoing elucidation of SIP1’s contribution to both physiological tone and pathological conditions.

Acknowledgments

We thank Dr. Yugesh Kharel (University of Virginia, Charlottesville, VA) for determination of sphingosine kinase activity in vitro and guidance for Western blotting techniques; Dr. Andrew Morris (University of Kentucky, Lexington, KY) for technical expertise and assistance provided during the course of our establishing LC-MS instrumentation capability; Dr. Ruth Stornetta (University of Virginia) for technical expertise in performing perfusion of mouse vascular culture for pulmonary vascular permeability studies; Gina Wimer (University of Virginia) for tail vein injections into mice; and Marie Burdick (University of Virginia) for guidance concerning the Lewis lung carcinoma model. VPC44116 was provided by Dr. Frank Foss Jr. (University of Texas, Arlington, TX). The plasmid encoding the C-terminal GFP-tagged human SIP1 receptor was a gift from Dr. Timothy Hla (University of Connecticut, Storrs, CT). The S1pr3(-/-) mice were a gift from Dr. Richard Pria (National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD).

Authorship Contributions

Participated in research design: Kennedy and Lynch.
Conducted experiments: Kennedy, David, and Peyruchaud.
Contributed new reagents or analytic tools: Zhu, Huang, Tomsg, Mathews, and Macdonald.
Performed data analysis: Kennedy, Tomsg, and David.
Wrote or contributed to the writing of the manuscript: Kennedy, Tomsg, and Lynch.

References

Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacol 22:3099–3108.


Address correspondence to: Dr. Kevin R. Lynch, University of Virginia, 1340 Jefferson Park Avenue, P.O. Box 800735, Jordan Hall, Room 5227, Charlottesville, VA 22908-0735. E-mail: krl2z@virginia.edu